Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Simple Summary Immunotherapy in the form of Immune Checkpoint Inhibitors which currently represent one of the staples of advanced Non-Small Cell Lung Cancer treatment. However, as of today, no prognostic factors are taken in account to shape immunotherapy-treated patient selection and management according to the most authoritative international guidelines. Therefore, the identification and evaluation of possible prognostic factors in this subset of patients represent an extremely interesting and relevant topic.Abstract Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 of the cases and for 1,796,144 of the cancer-related deaths, representing the second most common cancer in female patients, the most common cancer in male patients, and the second most common cancer in male and female patients) and the current lack of recommendations in terms of prognostic factors for patients selection and management, this article aims to provide an overview of the current landscape in terms of currently available immunotherapy treatments and the most promising assessed prognostic biomarkers, highlighting the current state-of-the-art and hinting at future challenges.